New drug trial offers hope for patients with rare kidney disease
NCT ID NCT06642909
Summary
This study is testing a new drug called Zuberitamab (HS006) for people with primary membranous nephropathy, a serious autoimmune kidney disease that causes protein loss. It will compare Zuberitamab to an existing drug, cyclosporine, to see which is better at reducing protein in the urine and protecting kidney function. The goal is to find a more effective treatment to control this disease and prevent long-term kidney damage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.